Article
Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release.
Hepatology (Baltimore, Md.) - 1 Feb 2014
Foster Toshana L, Thompson Gary S, Kalverda Arnout P, Kankanala Jayakanth, Bentham Matthew, Wetherill Laura F, Thompson Joseph, Barker Amy M, Clarke Dean, Noerenberg Marko, Pearson Arwen R, Rowlands David J, Homans Steven W, Harris Mark, Foster Richard, Griffin Stephen
Abstract excerpt
UNLABELLED: Current interferon-based therapy for hepatitis C virus (HCV) infection is inadequate, prompting a shift toward combinations of direct-acting antivirals (DAA) with the first protease-targeted drugs licensed in 2012. Many compounds are in the pipeline yet primarily target only three viral proteins, namely, NS3/4A protease, NS5B polymerase, and NS5A. With concerns growing over resistance, broadening the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.